- Home
- CATX
as 05-20-2024 4:00pm EST
$.
+$.
+.%
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 996.2M | IPO Year: | N/A |
| Target Price: | $2.10 | AVG Volume (30 days): | 5.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.21 - $1.91 | Next Earning Date: | 05-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -64.44% | Revenue Growth (next year): | 766.67% |
Share on Social Networks:
Stock Insider Trading Activity of Perspective Therapeutics Inc. (CATX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | CATX | 10% Owner | Mar 6 '24 | Buy | $0.95 | 60,431,039 | $57,409,487.05 | 116,773,394 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.71 | 18,579 | $13,191.09 | 230,134 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.71 | 5,127 | $3,640.17 | 235,261 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.71 | 57,121 | $40,555.91 | 292,382 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.72 | 42,879 | $30,872.88 | 335,261 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.70 | 3,500 | $2,450.00 | 338,761 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.64 | 21,235 | $13,590.40 | 211,555 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.64 | 4,031 | $2,579.84 | 190,320 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.54 | 50,000 | $27,000.00 | 186,289 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.55 | 25,000 | $13,750.00 | 136,289 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.59 | 8,513 | $5,022.67 | 111,289 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.61 | 14,850 | $9,058.50 | 102,776 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.61 | 12,250 | $7,472.50 | 87,926 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Dec 18 '23 | Buy | $0.26 | 10,000 | $2,600.00 | 10,000 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Dec 18 '23 | Buy | $0.32 | 13,680 | $4,377.60 | 23,680 | SEC Form 4 |
| Woods Lori A | CATX | Director | Dec 14 '23 | Buy | $0.27 | 152,962 | $41,284.44 | 1,519,738 | SEC Form 4 |
| Woods Lori A | CATX | Director | Dec 14 '23 | Buy | $0.27 | 32,238 | $8,704.26 | 1,366,776 | SEC Form 4 |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 hours ago
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
MT Newswires
5 days ago
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises
Associated Press Finance
5 days ago
Perspective Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
5 days ago
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire
17 days ago
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
GuruFocus.com
18 days ago
Lantheus Holdings Inc (LNTH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
GlobeNewswire
18 days ago
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
GlobeNewswire
20 days ago